56 related articles for article (PubMed ID: 28829788)
1. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.
Longley N; Jarvis JN; Meintjes G; Boulle A; Cross A; Kelly N; Govender NP; Bekker LG; Wood R; Harrison TS
Clin Infect Dis; 2016 Mar; 62(5):581-587. PubMed ID: 26565007
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa.
Walker SM; Cox E; Revill P; Musiime V; Bwakura-Dangarembizi M; Mallewa J; Cheruiyot P; Maitland K; Ford N; Gibb DM; Walker AS; Soares M;
J Int AIDS Soc; 2020 Mar; 23(3):e25469. PubMed ID: 32219991
[TBL] [Abstract][Full Text] [Related]
3. Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts.
Montgomery MP; Nakasujja N; Morawski BM; Rajasingham R; Rhein J; Nalintya E; Williams DA; Huppler Hullsiek K; Kiragga A; Rolfes MA; Donahue Carlson R; Bahr NC; Birkenkamp KE; Manabe YC; Bohjanen PR; Kaplan JE; Kambugu A; Meya DB; Boulware DR;
BMC Neurol; 2017 Jun; 17(1):110. PubMed ID: 28606065
[TBL] [Abstract][Full Text] [Related]
4. Impact of prior cryptococcal antigen screening on in-hospital mortality in cryptococcal meningitis or fungaemia among HIV-seropositive individuals in South Africa: a cross-sectional observational study.
Paccoud O; Shuping L; Mashau R; Greene G; Quan V; Meiring S; Govender NP;
Clin Microbiol Infect; 2023 Aug; 29(8):1063-1069. PubMed ID: 37086780
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay.
Frola C; Guelfand L; Blugerman G; Szyld E; Kaufman S; Cahn P; Sued O; Pérez H
PLoS One; 2017; 12(6):e0178721. PubMed ID: 28617817
[TBL] [Abstract][Full Text] [Related]
6. Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program.
Wake RM; Govender NP; Omar T; Nel C; Mazanderani AH; Karat AS; Ismail NA; Tiemessen CT; Jarvis JN; Harrison TS
Clin Infect Dis; 2020 Apr; 70(8):1683-1690. PubMed ID: 31179488
[TBL] [Abstract][Full Text] [Related]
7. Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy-Experienced Ugandans With Virologic Failure.
Mpoza E; Rajasingham R; Tugume L; Rhein J; Nabaggala MS; Ssewanyana I; Nyegenye W; Kushemererwa GE; Mulema V; Kalamya J; Kiyaga C; Kabanda J; Ssali M; Boulware DR; Meya DB
Clin Infect Dis; 2020 Oct; 71(7):1726-1731. PubMed ID: 31679007
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of cryptococcal antigen (CrAg) among HIV-positive patients in Eswatini, 2014-2015.
Haumba SM; Toda M; Jeffries R; Ehrenkranz P; Pasipamire M; Ao T; Lukhele N; Mazibuko S; Mkhontfo M; Smith RM; Chiller T
Afr J Lab Med; 2020; 9(1):933. PubMed ID: 32832407
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of cryptococcal antigen screening at CD4 counts of 101-200 cells/µL in Botswana.
Tenforde MW; Muthoga C; Ponatshego P; Ngidi J; Mine M; Greene G; Jordan A; Chiller T; Larson BA; Jarvis JN
Wellcome Open Res; 2021; 6():55. PubMed ID: 35087954
[No Abstract] [Full Text] [Related]
10. Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy.
Smith-Uffen M; Park J; Parsonson A; Kiely BE; Vasista A
Oncologist; 2024 May; ():. PubMed ID: 38768122
[TBL] [Abstract][Full Text] [Related]
11. Centralized or Onsite Testing? Examining the Costs of Water Quality Monitoring in Rural Africa.
Trimmer JT; Delaire C; Marshall K; Khush R; Peletz R
Environ Sci Technol; 2024 Jun; ():. PubMed ID: 38872464
[TBL] [Abstract][Full Text] [Related]
12. National Health Laboratory Service (NHLS) changes the method of LDL-cholesterol calculation in South Africa.
Pillay T; Rossouw HM; Steyn N; Carelse A
S Afr Med J; 2023 Dec; 114(1):16. PubMed ID: 38525620
[No Abstract] [Full Text] [Related]
13. High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients.
Wake RM; Britz E; Sriruttan C; Rukasha I; Omar T; Spencer DC; Nel JS; Mashamaite S; Adelekan A; Chiller TM; Jarvis JN; Harrison TS; Govender NP
Clin Infect Dis; 2018 Feb; 66(5):686-692. PubMed ID: 29028998
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries.
Rajasingham R; Nalintya E; Israelski DM; Meya DB; Larson BA; Boulware DR
Med Mycol; 2022 Feb; 60(2):. PubMed ID: 35026017
[TBL] [Abstract][Full Text] [Related]
15. Using routine health information data for research in low- and middle-income countries: a systematic review.
Hung YW; Hoxha K; Irwin BR; Law MR; Grépin KA
BMC Health Serv Res; 2020 Aug; 20(1):790. PubMed ID: 32843033
[TBL] [Abstract][Full Text] [Related]
16. Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
Faini D; Kalinjuma AV; Katende A; Mbwaji G; Mnzava D; Nyuri A; Glass TR; Furrer H; Hatz C; Boulware DR; Letang E
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):205-213. PubMed ID: 30422904
[TBL] [Abstract][Full Text] [Related]
17. Estimating the cost-per-result of a national reflexed Cryptococcal antigenaemia screening program: Forecasting the impact of potential HIV guideline changes and treatment goals.
Cassim N; Coetzee LM; Schnippel K; Glencross DK
PLoS One; 2017; 12(8):e0182154. PubMed ID: 28829788
[TBL] [Abstract][Full Text] [Related]
18. Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa.
Cassim N; Schnippel K; Coetzee LM; Glencross DK
PLoS One; 2017; 12(2):e0171675. PubMed ID: 28166254
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
